MEROPENEM FOR INJECTION 500 MG
MEROPENEM (MEROPENEM TRIHYDRATE) : 500 MG · DIN 02378787 · SANDOZ CANADA INCORPORATED
Health Canada status: MARKETED
What is MEROPENEM FOR INJECTION?
MEROPENEM FOR INJECTION 500 MG contains MEROPENEM (MEROPENEM TRIHYDRATE) : 500 MG. It is listed in the Health Canada Drug Product Database under DIN 02378787, held by SANDOZ CANADA INCORPORATED, supplied as POWDER FOR SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 26-Jan-2012. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is MEROPENEM FOR INJECTION used for?
Treatment of susceptible infections: Lower Respiratory Tract, Urinary Tract, Intra-abdominal, Gynecologic, Skin/Skin Structure, Bacterial Meningitis, and Bacterial Septicemia.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02378787 |
|---|---|
| Brand name | MEROPENEM FOR INJECTION |
| Generic / active ingredient | MEROPENEM (MEROPENEM TRIHYDRATE) : 500 MG |
| Manufacturer | SANDOZ CANADA INCORPORATED |
| Strength | 500 MG |
| Dosage form | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | J01DH02 MEROPENEM |
| AHFS class | 08:12.07.08 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 26-Jan-2012 |
| Original market date | 2012-01-26 00:00:00 |
How is it administered?
Adults: 500 mg to 1 g IV every 8 hours (up to 2 g for meningitis). Pediatrics (≥3 months): 10 to 40 mg/kg every 8 hours. Administer as IV infusion (15-30 min) or bolus (5 min).
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Freshly prepared solutions should be used whenever possible. (Specific temperature range not provided in text snippet, though stability section is referenced).
How is it supplied?
500 mg and 1 g vials.
Contraindications
Hypersensitivity to any component or anaphylactic reactions to β-lactam antibiotics.
Warnings and precautions
Serious hypersensitivity/anaphylactic reactions; potential for seizures (especially with renal impairment/CNS lesions); Clostridium difficile-associated disease (CDAD); SCAR.
Is MEROPENEM in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by EUGIA PHARMA INC., last seen 21 Aug 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code J01DH02 MEROPENEM. 15 of 26 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| MEROPENEM FOR INJECTION | 1 G | POWDER FOR SOLUTION | JAMP PHARMA CORPORATION | MARKETED | DIN 02536374 |
| MEROPENEM FOR INJECTION | 1 G | POWDER FOR SOLUTION | EUGIA PHARMA INC. | MARKETED | DIN 02528827 |
| MEROPENEM FOR INJECTION | 1 G | POWDER FOR SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02378795 |
| MEROPENEM FOR INJECTION | 1 G | POWDER FOR SOLUTION | STERIMAX INC | MARKETED | DIN 02493349 |
| MEROPENEM FOR INJECTION | 1 G | POWDER FOR SOLUTION | AURO PHARMA INC | MARKETED | DIN 02462893 |
| MEROPENEM FOR INJECTION | 500 MG | POWDER FOR SOLUTION | AURO PHARMA INC | MARKETED | DIN 02462885 |
| MEROPENEM FOR INJECTION | 500 MG | POWDER FOR SOLUTION | EUGIA PHARMA INC. | MARKETED | DIN 02528819 |
| MEROPENEM FOR INJECTION | 500 MG | POWDER FOR SOLUTION | STERIMAX INC | MARKETED | DIN 02493330 |
| MEROPENEM FOR INJECTION USP AND SODIUM CHLORIDE INJECTION USP | 1 G | POWDER FOR SOLUTION | B. BRAUN MEDICAL INC | MARKETED | DIN 02544342 |
| MEROPENEM FOR INJECTION USP AND SODIUM CHLORIDE INJECTION USP | 500 MG | POWDER FOR SOLUTION | B. BRAUN MEDICAL INC | MARKETED | DIN 02544334 |
Who else supplies MEROPENEM worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. MEROPENEM appears in 852 registered pack listings across 8 markets, published on 7 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.